Understand the source comparison
Best Follistatin-344 Dosage for Muscle Growth: Research Protocol Comparison
Johns Hopkins AAV-Follistatin Trial 200 mcg equivalent via gene therapy Continuous expression (gene delivery) 12 weeks 15% increase in lean mass; 12% increase in grip strength Gene therapy bypasses pharmacokinetic limitations of exogenous peptide. Superior myo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Johns Hopkins AAV-Follistatin Trial
- 200 mcg equivalent via gene therapy
- Continuous expression (gene delivery)
- 12 weeks
- 15% increase in lean mass; 12% increase in grip strength
- Gene therapy bypasses pharmacokinetic limitations of exogenous peptide. Superior myostatin suppression but not practical for standard research
- Molecular Endocrinology Murine Study
- 100 mcg/kg daily (roughly 150–200 mcg human equivalent)
- Once daily subcutaneous
- 8 weeks
- 27% muscle fiber hypertrophy in aged mice
- Demonstrates dose-dependent efficacy. Daily administration sufficient in rodent models due to faster metabolism
- Independent Research Protocol (Human Equivalent Dosing)
- 300 mcg daily divided (150 mcg AM, 150 mcg PM)
- Twice daily subcutaneous
- 8–12 weeks
- Anecdotal lean mass gains 3–6 kg; strength increases 8–15% on compound lifts
- Most common real-world protocol. Divided dosing maintains plasma stability; results vary based on training intensity and caloric surplus
- Low-Dose Maintenance Protocol
- 100 mcg daily
- 4–8 weeks
- Minimal measurable change in body composition; slight strength retention during caloric deficit
- Subtherapeutic for anabolic effect. May preserve muscle during cutting phases but insufficient for hypertrophy